Protalix BioTherapeutics, Inc. (PLX) Operating margin 2016–2025
Protalix BioTherapeutics, Inc. (PLX) operating margin by fiscal year — reported operating income divided by reported revenue.
-10.4%FY2025 · since FY2016: -360.5% → -10.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -10.4% | -17.8 pp |
| FY2024 | 7.3% | -8.6 pp |
| FY2023 | 16.0% | +43.3 pp |
| FY2022 | -27.3% | +26.0 pp |
| FY2021 | -53.4% | -57.7 pp |
| FY2020 | 4.3% | +23.9 pp |
| FY2019 | -19.6% | +36.8 pp |
| FY2018 | -56.4% | +107.4 pp |
| FY2017 | -163.8% | +196.7 pp |
| FY2016 | -360.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice